Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -103,175 | -55,463 | -29,281 | -80,604 | -51,780 |
| Depreciation Amortization | -1,278 | -1,041 | -667 | -4,938 | -3,833 |
| Accounts payable and accrued liabilities | 8,625 | 1,722 | -150 | 1,141 | 403 |
| Other Working Capital | 24,534 | 7,054 | 1,634 | 6,175 | 414 |
| Other Operating Activity | -3,380 | 1,807 | 1,924 | 7,466 | 5,851 |
| Operating Cash Flow | $-74,674 | $-45,921 | $-26,540 | $-70,760 | $-48,945 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 66,400 | 33,358 | 14,497 | -84,872 | -104,248 |
| PPE Investments | -91 | -68 | -49 | -515 | -336 |
| Investing Cash Flow | $66,309 | $33,290 | $14,448 | $-85,387 | $-104,584 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 65,287 | N/A | N/A | 161,883 | 161,847 |
| Financing Cash Flow | $65,287 | $N/A | $N/A | $161,883 | $161,847 |
| Beginning Cash Position | 33,824 | 33,824 | 33,824 | 28,088 | 28,088 |
| End Cash Position | 90,746 | 21,193 | 21,732 | 33,824 | 36,406 |
| Net Cash Flow | $56,922 | $-12,631 | $-12,092 | $5,736 | $8,318 |
| Free Cash Flow | |||||
| Operating Cash Flow | -74,674 | -45,921 | -26,540 | -70,760 | -48,945 |
| Capital Expenditure | -91 | -68 | -49 | -515 | -336 |
| Free Cash Flow | -74,765 | -45,989 | -26,589 | -71,275 | -49,281 |